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Introduction: Patients with thoracic tumors that recur after irradiation 
currently have limited therapeutic options. Retreatment using stereotactic 
ablative radiotherapy (SABR) is appealing for these patients because of its 
high conformity but has not been studied extensively. Here we report our 
experience with SABR for lung tumors in previously irradiated regions.
Methods: We conducted a retrospective study of patients with pri-
mary lung cancer or metastatic lung tumors treated with SABR. We 
identified 17 such tumors in 15 patients and compared their outcomes 
with those of a cohort of 135 previously unirradiated lung tumors 
treated with SABR during the same time period.
Results: Twelve-month local control (LC) for retreated tumors was 
65.5%, compared with 92.1% for tumors receiving SABR as initial 
treatment. Twelve-month LC was significantly worse for reirradiated 
tumors in which the time interval between treatments was 16 months 
or less (46.7%), compared with those with longer intertreatment 
intervals (87.5%). SABR reirradiation did not lead to significant 
increases in treatment-related toxicity.
Conclusions: SABR for locally recurrent lung tumors arising in 
previously irradiated fields seems to be feasible and safe for appro-
priately selected patients. LC of retreated lesions was significantly 
lower, likely owing to the lower doses used for retreatment. Shorter 
time to retreatment was associated with increased risk of local fail-
ure, suggesting that these tumors may be particularly radioresistant. 
Our findings suggest that dose escalation may improve LC while 
maintaining acceptable levels of toxicity for these patients.
Key Words: Stereotactic ablative radiotherapy/Stereotactic body 
radiation therapy, Reirradiation, Lung cancer, Metastases, Biologically 
effective dose.
(J Thorac Oncol. 2012;7: 1462–1465)
A significant fraction of both early-stage and locally advanced lung cancer patients are treated with radiotherapy. In recent 
years, stereotactic ablative radiotherapy (SABR), also known as 
stereotactic body radiation therapy, has emerged as a promising 
treatment for early-stage, medically inoperable non–small-cell 
lung cancer (NSCLC) and oligometastatic lung tumors.1,2 Local 
recurrence in these patients is uncommon and is usually reported 
to be less than 10%.3,4 In contrast, patients with locally advanced 
NSCLC are often treated with conventionally fractionated radia-
tion therapy (CFRT), which is associated local recurrence rates 
of approximately 50%.5 In addition, patients with NSCLC are 
prone to developing second malignancies, which may arise 
within or near previously irradiated areas. The optimal manage-
ment of patients with recurrent or new tumors in previously irra-
diated regions remains a challenging therapeutic problem.
Options for the treatment of locally recurrent disease are 
limited, mainly consisting of chemotherapy, resection, or reir-
radiation.6,7 Reirradiation of locoregional failures with CFRT 
is controversial, given concerns regarding radioresistance of 
previously irradiated tumors and the risks of exceeding the 
radiation tolerances of adjacent normal tissue. Published 
reports of reirradiation of recurrent lung tumors using CFRT 
describe varying doses and target volumes and are primarily 
palliative in intent.8 SABR represents an intriguing treatment 
approach for locally recurrent lung tumors. However, little is 
known about the efficacy and toxicity of such an approach. 
Here we report our institutional experience using SABR for 
the treatment of locally recurrent thoracic tumors.
MATERIALS AND METHODS
We conducted a retrospective review of all patients 
treated with lung tumor SABR at the Stanford Cancer Institute 
from January 2004 to June 2010, who had been previously 
treated with CFRT or SABR and who had biopsy-confirmed 
recurrent or second lung tumor occurring within the previ-
ous treatment field. We compared their outcomes with the 
outcomes of a cohort of previously unirradiated lung tumors 
treated with SABR during the same time period.
We have previously described our techniques for SABR.9 
We obtained follow-up diagnostic computed tomographic scan 
of the thorax and/or positron emission tomography (PET)-
computed tomography (CT) at approximately 2 months post-
SABR, then every 3 months for the first year, every 4 months 
for the second year, every 6 months for the third year, and 
yearly thereafter. Local failure (LF) was defined as recurrence 
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within the planning target volume (PTV). Local control (LC) 
was defined as lack of LF. Disease progression was defined as 
LF or documented disease outside the PTV. Local or distant 
failure was documented by biopsy, or if biopsy was not feasible, 
was defined as radiographic or clinical evidence of progression 
that led to a change in management, including institution of 
chemotherapy, reirradiation, or surgical resection of the treated 
tumor. The date of progression was backdated to the first evi-
dence of radiographic or clinical progression as determined by 
the treating physicians. We scored esophageal injury, radiation 
pneumonitis, and chest-wall toxicity. LC, progression-free sur-
vival (PFS), and overall survival (OS) were compared using 
the Kaplan-Meier method. Statistical significance was assessed 
using the log-rank test. Potential toxicity differences between 
the two treatment groups were assessed using the χ2 test.
RESULTS
Patient, tumor, and treatment characteristics are shown in 
Table 1. A total of 15 patients with 17 lung tumors met the cri-
teria for this analysis. Median follow-up was 15 months (range, 
4–65 months). The control group consisted of 111 patients 
with 135 lung tumors. Prescribed biologically effective dose 
(BED) at the PTV margin for the reirradiation cohort’s initial 
treatment ranged from 60 to 112.5 Gy (median 87.5 Gy), and 
from 60 to 112.5 Gy for the SABR retreatment course (median 
80 Gy). Median total BED (including the original course) was 
157.6 and 87.5 Gy for the reirradiation cohort and control 
groups, respectively. Only one reirradiated tumor was retreated 
with a BED of more than 100 Gy. The median time from prior 
treatment in the reirradiation cohort was 16 months.
LC for all treated tumors is shown in Figure 1A. Twelve-
month actuarial LC was 65.5% for the reirradiated group and 
92.1% for the control group (p < 0.001). There were a total of 
seven LFs in the reirradiation cohort and four of these were 
accompanied by regional or distant failure. Twelve-month 
actuarial PFS and OS did not differ significantly between the 
two groups and is shown in Figures 1B and C. Twelve-month 
actuarial PFS and OS for the reirradiated group were 58.2% 
and 80%, respectively. For the control group, 12-month actu-
arial PFS and OS were 71.1% and 92.9%, respectively.
We observed a significant difference in LC when the 
time interval from the initial treatment to the second treatment 
was less than or equal to the median of 16 months. As seen 
in Figure 1D, 12-month actuarial LC for tumors whose time 
interval between treatments was 16 months or less was 46.7%, 
compared with 87.5% for tumors in which the time interval 
between radiation treatments exceeded 16 months (p = 0.042). 
Although there were trends toward worse actuarial PFS and 
OS in tumors with short retreatment intervals compared with 
those with longer median intervals (12-month PFS 46.7% ver-
sus 70% p = 0.099) and OS (66.7% versus 100%, p = 0.286), 
these were not statistically significant.
Tumors that were reirradiated after an initial course of 
SABR are a particularly interesting subset of our reirradia-
tion cohort given the high total doses they received (Fig. 2). 
This group includes four patients, who received initial SABR 
regimens of 25 Gy in a single fraction (three patients) and 50 
Gy in four fractions (one patient), and who were retreated with 
regimens of 20/1 (two patients), 45/4 (one patient), and 50/4 
(one patient). Of these four patients, three remain controlled 
both locally and distantly after the second course of SABR. 
The remaining patient failed simultaneously in the regional 
lymph nodes and locally 7 months after retreatment.
Overall toxicity was extremely low, and no significant 
differences were seen between the reirradiated and control 
groups. Pneumonitis of grade 2 or higher was observed in 
none of the reirradiated patients and 13 (11.6%) of the control 
patients (p = 0.16). Chest-wall toxicity was observed in one 
(6.7%) of the reirradiated patients and 11 (10%) of the control 
patients (p = 0.69). Esophagitis was only observed in a single 
patient in the control group (0.9%). No grade 4 or higher tox-
icities were observed. Patients who were retreated with SABR 
TABLE 1.  Patient, Tumor, and Treatment Characteristics
Parameter Reirradiated Previously Unirradiated
Patients 15 111
Tumors 17 135
Median follow-up (mos) 15 11
Male 7 (41%) 61 (45%)
Female 10 (59%) 74 (55%)
Age, median (range), years 66 (49–92) 73 (31–93)
GTV, median (range) 14.2 (2-57.7) ml 6.7 (0.2–80) ml
PTV, median (range) 31.6 (7.4–119.7) ml 28.2 (2.7–224) ml
Primary lung tumors 12 (71%) 96 (71%)
Metastases 5 (29%) 39 (29%)
Peripheral 11 (65%) 111 (82%)
Central 6 (35%) 24(18%)
Median BED of course #1 87.5 (60–112.5) Gy
Median BED of course #2 80 (60–112.5) Gy
Dose/fraction of course #2
 20 Gy/1 5
 40Gy/4 4
 25Gy/1 3
 30Gy/3 2
 45Gy/4 1
 50Gy/5 1
 50Gy/4 1
Median total BED 157.6 Gy
Median BED for control  
group
87.5 Gy
Median time from prior  
radiation
16 (5–80) mo
“In field” reirradiation 17
Reirradiation of previously  
irradiated tumor
12
Course #1 radiation  
technique
3-dimensional CRT 10
IMRT 3
SABR 4
Concurrent chemo with 
course #1
6
GTV, gross tumor volume; PTV, planning target volume; BED, biologically effective 
dose; CRT, chemoradiotherapy; IMRT, intensity modulated radiation therapy; SABR, 
stereotactic ablative radiotherapy.
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after developing LF from a previous course of SABR also tol-
erated reirradation well, with only a single episode of grade-2 
chest-wall toxicity occurring in this group. One patient with a 
central lesion near the aortic arch developed ipsilateral vocal-
cord paralysis, which was possibly secondary to recurrent 
laryngeal nerve toxicity.
DISCUSSION
The treatment of patients with isolated, locally relapsed 
lung cancer is a difficult clinical problem, especially in the 
setting of previous radiation treatment. SABR is an appealing 
treatment option, but little is known about its use in the setting 
of reirradiation. At our institution, we have been employing 
SABR for such patients, using relatively conservative doses to 
decrease the chance of normal tissue toxicity. In this study, we 
present our initial experience of using SABR for previously 
irradiated lung tumors.
Compared with a cohort of primary lung tumors treated 
during the same time period, reirradiated patients displayed 
significantly reduced LC. This is most likely attributable to 
the fact that we employed retreatment fractionation regimens 
with BEDs less than 100 Gy because of initial concerns about 
potential toxicity of reirradiation.
Although high-dose reirradiation raises concerns about 
potential side effects, we observed relatively low levels of 
toxicity, similar to those seen in SABR in previously unirra-
diated patients. Kelly et al.10 recently reported a series of 36 
patients who received SABR after thoracic CFRT, of which 
11 were analogous to our reirradiation cohort because they 
developed recurrences in prior high-dose regions. The authors 
treated the majority of patients with 50 Gy in four fractions 
and noted excellent LC rates of 92%. However, high rates of 
toxicity were seen in this series, with 33% grade-3 toxicity 
and more than 50% of patients experiencing grade 2 or higher 
FIGURE 1. Outcomes of SABR reirradiation after local recurrence. A, Kaplan-Meier estimates of LC for reirradiated tumors 
(black line), compared with the control group of tumors that had not received prior irradiation (gray line). B, Kaplan-Meier 
estimates of progression-free survival of reirradiated (black line) and control (gray line) patients. C, Kaplan-Meier estimates of 
overall survival (OS) of reirradiated (black line) and control (gray line) patients. D, Kaplan-Meier estimates of LC for reirradiated 
tumors with time to retreatment (TTR) ≤ 16 months (black line) or TTR > 16 months (gray line). The median TTR in this cohort 
was 16 months. LC, local control. 
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pneumonitis. This contrasts with our data, where lower levels 
of control were seen but with minimal toxicity. Another study 
by Seung et al.11 included eight patients and used radiation 
doses of 40 to 60 Gy in three to five fractions with reported 
LC rates in the range of 80% to 90%. Taken together, our 
findings and the two previous reports suggest that SABR for 
reirradiation can be performed safely and that it is possible 
to achieve high rates of LC. However, prospective studies are 
clearly needed to identify the optimal dose for SABR of previ-
ously irradiated tumors.
Significantly, we found that longer intervals between the 
initial treatment and reirradiation were associated with better 
local control. We also observed a trend for worse OS and PFS in 
patients with shorter time to initial recurrence. A similar obser-
vation with regard to OS has been reported in relapsed NSCLC 
patients reirradiated using CFRT.12 Notably, in the SABR reirra-
diation study by Seung et al. all but one of the eight patients had 
intervals of more than 15 months between the original course 
and SABR reirradiation. Their reported LC rate of 86% agrees 
with what we observed in patients who had had similarly long 
intertreatment intervals. These findings provide useful prog-
nostic information and suggest that dose escalation even at the 
risk of higher toxicity may be warranted for tumors with shorter 
intervals between initial treatment and reirradiation.
We also report on the outcomes of four patients who 
were retreated with SABR for LF after a previous course 
of SABR. To the best of our knowledge, these are the first 
reported data for such patients. Given the widespread adop-
tion of lung SABR, this clinical situation will arise more fre-
quently in the future. Currently, management options that may 
be considered for patients developing LF after SABR include 
chemotherapy and surgical resection in medically operable 
candidates.13,14 Our data suggest that repeat SABR may also 
be considered, although this approach needs to be prospec-
tively evaluated in a larger group of patients.
Limitations of our study include the retrospective nature 
of the analysis and its somewhat limited follow-up time. The 
study is also limited by heterogeneity in tumor type, because 
it includes both metastatic tumors and primary lung tumors. It 
should also be noted that our cohort did not include any recur-
rent tumors very close to the spinal cord or brachial plexus.
In conclusion, our findings demonstrate that SABR is a 
promising tool for the salvage treatment of recurrent tumors 
that were previously irradiated. Prospective studies establish-
ing the optimal dose and fractionation schedule are needed.
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FIGURE 2. Example of SABR reirradiation for a patient with local recurrence after an initial course of SABR. A, First treatment 
course of SABR for a right lower lobe non–small-cell lung cancer. Prescribed dose was 50 Gy in four fractions. B, Second course 
of SABR after biopsy confirmed local progression. Prescribed dose was 20 Gy in a single fraction. Volumes: orange  shading = 
gross tumor volume, red shading = planning target volume. Isodose curves: magenta 50%, yellow 100%, and cyan 110% 
of prescription dose. C, Six-month follow-up positron emission tomography/computed tomography scan showing shrinkage, 
metabolic response, and mild local inflammation. SABR, stereotactic ablative radiotherapy.
